Adalimumab-Induced Clinical Remission in Refractory and Long-Standing Systemic Juvenile Idiopathic Arthritis: Case Report

Alessandro Consolaro, Stefano Lanni, Alberto Martini, Angelo Ravelli
2014 Annals of the Pediatric Rheumatology (APR)  
The American College of Rheumatology guidelines for the treatment of systemic juvenile idiopathic arthritis (JIA) with active arthritis and without active systemic features recommend initiation or addition of a tumor necrosis factor-α inhibitor in patients with moderate-to-severe disease activity who fail to respond to methotrexate therapy. We describe a child with difficult-to-treat systemic-onset JIA with a polyarticular course who achieved clinical remission on medication for the first time
more » ... for the first time in over seven years after the initiation of adalimumab treatment.
doi:10.5455/apr.031720142111 fatcat:i7d3gsictnhjzknkvunktr7vqy